Reflecting on 2025, the biotech industry considerably advanced in gene editing, oncology, and AI-driven drug discovery and saw increased M&A activity. We also witnessed a notable shift from oncology innovations beginning to influence treatments in immunology and autoimmune diseases.

As the year draws to a close, we’re proud to celebrate the milestones of some of our clients, whom we’ve supported at various stages of their business journeys.

Sonoma Biotherapeutics Private, immunology and autoimmune disease Sonoma Biotherapeutics reported encouraging interim Phase 1 safety and efficacy data for SBT-77-7101 in refractory rheumatoid arthritis. And with co-founder Fred Ramsdell receiving the 2025 Nobel Prize in Physiology or Medicine for his pioneering Treg-cell research, Sonoma closed an extraordinary year of scientific recognition and therapeutic progress. Discover our work here: View here.

Avenzoar Pharmaceuticals Private, oncology This year, we partnered with Avenzoar to translate their complex oncology science into a clear, compelling narrative for investors, refining messaging and creating a cohesive brand and investor presentation. The result showcased their scientific edge with confidence and clarity, supporting the team as they advance toward clinical development. Discover our work for Avenzoar here: View here.

Vie Ventures Private, venture capital Vie Ventures is a venture firm combining capital and patient-focused philanthropy to support biotech companies developing therapies for autoimmune and immune-mediated diseases. With this innovative model, Vie Ventures is uniquely positioned to accelerate development and help the next generation of therapies reach patients faster. View the website we built for them: View here.

Metagenomi Public (NASDAQ: MGX), gene editing This year brought extraordinary momentum for Metagenomi, from publishing new data in Nature Communications on a novel “all-in-one” mRNA-based CAST gene-integration system to sharing promising preclinical results showing curative FVIII activity in Hemophilia A. Discover our work for Metagenomi here: View our work.

Enlivex Public (NASDAQ: ENLV), cell therapy for inflammatory diseases Innovation in biotech takes many forms, and Enlivex exemplified this in 2025 with positive 6-month topline data showing durable pain reduction in knee osteoarthritis and the launch of a forward-thinking digital asset strategy. Discover our work for Enlivex here: View our work.

Lexeo Therapeutics Public (NASDAQ: LXEO), gene therapy for cardiovascular and neurological disorders We’re proud to celebrate Lexeo Therapeutics’ standout progress, from raising funds to advance its gene therapy programs to securing Breakthrough Therapy designation and reporting encouraging Phase 1/2 data for its Friedreich’s Ataxia cardiomyopathy program. Discover our work for Lexeo here: View our work.

NanoCell Therapeutics Private, in vivo gene therapy NanoCell Therapeutics made major strides this year, publishing groundbreaking data showing successful in-body generation of CAR-T cells using their non-viral, DNA-based in vivo gene therapy platform, and securing prestigious EU funding for their collaborative QUIET-CAR program.

Bantam Pharmaceutical Private, oncology Bantam Pharmaceutical advanced from discovery to clinical development, activating its first Phase 1 trial site at MD Anderson for BTM-3566 and gaining approval to expand into additional sites in Canada.

BrainXell Therapeutics Private, regenerative medicine BrainXell Therapeutics made powerful strides in regenerative medicine, from welcoming new CEO Katherine Vega Stultz, to advancing promising preclinical data for BXT-110, their autologous iPSC-derived neuronal therapy for Parkinson’s disease. BrainXell closes 2025 with exceptional momentum and a clear path forward.

Opna Bio Private, oncology Opna Bio made significant progress, from receiving orphan drug designation for OPN-6602 and advancing multifunctional protein degraders with full tumor regressions in preclinical studies to reporting encouraging Phase 1 data for OPN-2853 in advanced myelofibrosis. Discover our work for Opna Bio here: View our work.

AmMax Bio Private, oncology AmMax Bio advanced their lead program AMB-066 into Phase 2a for colorectal cancer patients with minimal residual disease, dosing the first patient and marking a major milestone for a community with limited options. Coupled with their presentation at BIO-Europe Spring, these achievements highlight a year of scientific progress and steadfast commitment to delivering new hope to patients. Discover our work for AmMax Bio here: View our work.

Addition Therapeutics Private, genetic medicine Addition Therapeutics made strides in genetic medicine with a novel approach using therapeutic RNA and a specialized reverse transcriptase to precisely insert DNA into safe-harbor sites, enabling durable and controlled genetic changes. We worked with Addition on their investor materials and launched them out of stealth.

We take great pleasure in witnessing our clients’ growth and success as they progress in their drug development journey. As we approach 2026, we wish all our clients the greatest achievements in each stage of their ventures.

Are you preparing for a significant milestone next year that deserves investor attention?

Contact us to schedule your project for next year, whether it’s updating your story and investor presentation, showcasing your scientific approach via illustrative MOA slides or developing a stand-alone pitch on your website.

About Theoria Creative
Theoria Creative is a marketing firm, enabling life sciences companies to clearly communicate complex science to investors, partners, and peers. We develop communication strategy, messaging, positioning, and prepare a set of illustrated materials that help companies clearly and succinctly articulate their value at high stakes meetings.

View examples of our client work here.

Follow us on LinkedIn. Subscribe to our news.